The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Simple Summary Hepatocellular carcinoma (HCC) represents one of the main indications
for liver transplantation. Over recent years, immune checkpoint inhibitor (ICI) therapy has …

Clinical trials studying immune checkpoint inhibitors (ICIs) have excluded
immunocompromised patients, and little is known about the safety and efficacy of …

Immune checkpoint inhibitors are now approved for more than 50 indications, and
increasing numbers of patients with advanced cancer are receiving immunotherapy …

Background and aims Treatment of de novo malignancies and recurrent hepatocellular
carcinoma with immune checkpoint inhibitors (ICI) in liver transplant recipients (LT) is an …

Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver
transplantation (LT) in hepatocellular carcinoma patients are rapidly increasing. However …

Background Based on favourable outcomes in clinical trials, immune checkpoint inhibitors
(ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte …

De novo malignancies (DNMs) following liver transplantation (LT) have been reported as 1
of the major causes of late mortality, being the most common cause of death in the second …

Abstract Treatment modalities for hepatocellular carcinoma (HCC) vary from surgical
techniques and interventional radiologic strategies to systemic therapy. For the latter, the …

Background Treatment for de novo or recurrent tumors of liver transplantation (LT) recipients
is challenging and immune checkpoint inhibitor (ICI) is recently well developed and could be …